Nitric oxide: package leaflet

INOmax contains nitric oxide, a gas used for the treatment of
▪ newborn babies with lung failure associated with high blood pressure in the lungs, a condition known as hypoxic respiratory failure. When inhaled, this gas mixture can improve the flow of blood through the lungs, which may help to increase the amount of oxygen that reaches your baby’s blood.
▪ newborn babies, babies, children, teenagers 0-17 years and adults with high blood pressure in the lungs, connected with heart surgery. This gas mixture can improve heart function and increase the flow of blood through the lungs, which may help to increase the amount of oxygen that reaches the blood.

Do not use INOmax
- If you (as the patient) or your child (as the patient) are allergic (hypersensitive) to nitric oxide or any other ingredients of INOmax (see section 6 ‘further information’ where the full list of ingredients is provided).
- If you have been told that you (as the patient) or your child (as the patient) have an abnormal circulation within the heart.
Warnings and precautions
Inhaled nitric oxide may not always be effective and thus other therapies may be considered necessary for you or your child.
Inhaled nitric oxide may influence the oxygen carrying capacity of the blood. This will be monitored by blood samples and if required the dose of inhaled nitric oxide must be reduced.
REG-15307/v.43
Page 43/56

Nitric oxide may react with oxygen forming nitrogen dioxide that may cause airway irritation. Your or your child’s doctor will undertake monitoring of nitrogen dioxide and in case of elevated values the INOmax therapy will be adjusted, decreased accordingly.
Inhaled nitric oxide may have a mild but influence on the platelets (components that help the blood to clot) of you or your child and any signs of bleeding and or haematoma should be observed. If you see any signs or symptoms that may be associated to bleeding, you should directly inform the doctor.
No effect of inhaled nitric oxide has been documented in newborn babies with a malformation where the diaphragm is not fully complete, so called ‘congenital diaphragmatic hernia’.
In newborn babies with special malformations of the heart, ‘what doctors calls congenital heart defects’ inhaled nitric oxide may cause a worsening of the circulation.
Cases of fluid retention in the lungs have been reported with nitric oxide in patients with disease due to a blocked or narrow vein in the lungs. If you (as a patient) or your child (as a patient) develops shortness of breath or difficulty breathing, contact your doctor immediately.
Children
INOmax should not be used in preterm baby < 34 weeks of gestational age.
Other medicines and INOmax
The doctor will decide when to treat you or your child with INOmax and with other medicines and will carefully supervise the treatment.
Please tell your doctor if you (as the patient) or your child (as the patient) are taking or have recently taken or used any other medicines, including medicines obtained without a prescription.
Some medicines can affect the ability of blood to carry oxygen. These include prilocaine (a local anaesthetic used for pain relief in association to minor painful procedures e.g. suturing, and minor surgical or diagnostic procedures) or glyceryl trinitrate (used to treat chest pain). Your doctor will take care to check that the blood can carry enough oxygen when you are taking these medicines.
Pregnancy and breastfeeding
INOmax is not recommended for use during pregnancy and breastfeeding.
Tell your doctor before treatment with INOmax if you are pregnant, think you could be pregnant or are breastfeeding Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Not relevant.
INOmax contains Nitrogen

Your doctor will decide the correct dose of INOmax and will administer INOmax to you or your child’s lungs through a system designed for delivering this gas. This delivery system will ensure that the correct amount of nitric oxide is delivered by diluting INOmax with an oxygen/air mixture immediately before giving it to you.
REG-15307/v.43
Page 44/56

For you or your child’s safety, the delivery systems intended for administration of INOmax are fitted with devices that constantly measure the amount of nitric oxide, oxygen, and nitrogen dioxide (a chemical formed when nitric oxide and oxygen are mixed) being delivered to the lungs.
Your doctor will decide how long you or your child should be treated with INOmax.
INOmax is given in dose of 10 to 20 ppm, (maximal dose 20 ppm in children and 40 ppm in adults) part per million of the gas that you or your child inhale. The lowest effective dose will be sought.
Therapy is usually required for about 4 days in newborn infants with lung failure associated with high blood pressure in the lungs. In children and adults with high blood pressure in the lungs, connected with heart surgery, INOmax is usually given for 24-48 hours. However, therapy with INOmax may last longer.
If you or your child receive more INOmax than you should
Too much of inhaled nitric oxide may influence the oxygen carrying capacity of the blood. This will be monitored by blood samples and if required the INOmax dose will be decreased and the administration of medicines such as vitamin C, methylene blue, or eventually blood transfusion, in order to improve the oxygen carrying capacity, may be considered.
If you stop using INOmax
Treatment with INOmax should not be stopped suddenly. Low blood pressure or a rebound increase in pressure in the lungs has been known to occur if treatment with INOmax is stopped suddenly without first lowering the dose.
At the end of treatment, the doctor will slowly lower the amount of INOmax being given to you or your child, so that the circulation in the lungs is able to adjust to oxygen/air without INOmax. Thus, it may take a day or two before you or your child is off INOmax therapy.
If you have any other questions on the use of this medicine, ask your doctor.

Like all medicines, this medicine can cause side effects, although not everybody gets them.
The doctor will examine you or your child closely for all side effects.
Side effects that are very commonly seen (affects more than 1 user in 10) in association with INOmax therapy include:
▪
Low platelet count.
Side effects that are commonly seen (affects more than 1 user in 100) in association with INOmax therapy include:
▪ low blood pressure, airless or collapsed lung.
Side effects that may be seen, but uncommonly (affects between 1 user in 100 and 1 user in 1000) are:
▪ increase in methaemoglobin, thus reduced oxygen carrying capacity.
Side effects that may be seen but the frequency is not known (frequency cannot be estimated from the available data) are:
▪
Bradycardia (low cardiac frequency) or too low amount of oxygen in the blood (oxygen desaturation/hypoxemia) due to sudden withdrawal of the treatment, ▪ Headache, dizziness, dry throat, or shortness of breath following accidental ambient air exposure to nitric oxide (e.g. leakage from equipment or cylinder).
REG-15307/v.43
Page 45/56

You should directly inform the personnel if you experience headache while being in close proximity to your child receiving INOmax.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, even after you or your child leave the hospital, please tell your doctor.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

Keep this medicine out of the sight and reach of children
Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.
INOmax therapy should only be used and handled by hospital personnel.
▪
INOmax cylinders should be stored secured in order to avoid falling and thus potentially causing harm.
▪
INOmax should be used and administered only by personnel specially trained in the use and handling of INOmax.
All regulations concerning handling of pressurised gas cylinders must be followed.
Storage is supervised by the specialists at the hospital. Gas cylinders are to be stored in well-ventilated rooms or in ventilated sheds where they are protected from rain and direct sunlight.
Protect the gas cylinders from shocks, falls, oxidising and flammable materials, moisture, sources of heat or ignition.
Storage in the pharmacy department
The gas cylinders should be stored in an airy, clean and locked place, for storage of medicinal gas only. Inside this place, a separate premise should be dedicated to the storage of nitric oxide gas cylinders.
Storage in the medical department
The gas cylinder should be put in an equipped site with appropriate material in order to hold the cylinder vertically.
When the gas cylinder is empty, do not discard. Empty gas cylinders will be collected by the supplier.

What INOmax contains
The active substance in INOmax is nitric oxide 400 ppm mol/mol. A 2 litre gas cylinder filled at 155 bar absolute brings 307 litres of gas under pressure of 1 bar at 15oC. A 10 litre gas cylinder filled at 155 bar absolute brings 1535 litres of gas under pressure of 1 bar at 15oC.
The other ingredient is nitrogen.
REG-15307/v.43
Page 46/56

What INOmax looks like and contents of the pack
Medicinal gas, compressed
A 2 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection and a standard valve hand-wheel.
A 2 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection and a INOmeter device equipped valve hand-wheel.
A 10 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection and a standard valve hand-wheel.
A 10 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection and a INOmeter device equipped valve hand-wheel.
INOmax is available in 2 litre and 10 litre aluminium gas cylinder.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Linde Healthcare AB
Rättarvägen 3
169 68 Solna
Sweden
Manufacturer
Linde France
Z.I. Limay Porcheville
3 avenue Ozanne
78440 Porcheville
France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Linde Gas Belgium N.V.
Borsbeeksebrug 34
B - 2600 Antwerpen
Tél/Tel.: +32 70 233 826 info.healthcare.be@linde.com
Lietuva
Linde Gas UAB
Didlaukio g. 69
LT - 08300 Vilnius
Tel.: +370 2787787 administracija.lt@linde.com
България
Linde Healthcare AB
Rättarvägen 3
S - 169 68 Solna
Швеция
Tel: +46 8 7311000 healthcare.se@linde.com
Luxembourg/Luxemburg
Linde Gas Belgium N.V.
Borsbeeksebrug 34
B - 2600 Antwerpen
Belgique/Belgien
Tél/Tel.: +32 70 233 826 info.healthcare.be@linde.com
REG-15307/v.43
Page 47/56

Česká republika
Linde Gas a.s.
U Technoplynu 1324
CZ - 198 00 Praha 9
Tel: +420 800 121 121 info.cz@linde.com
Magyarország
Linde Gáz Magyarország Zrt.
Illatos út 11/A.
H - 1097 Budapest
Tel.: +36 30 349 2237 tunde.bencze@linde.com
Danmark
Linde Gas A/S
Lautruphøj 2-6
DK - 2750 Ballerup
Tlf.: + 45 70 104 103 healthcare.dk@linde.com
Malta
Linde Medicale S.r.L
Via Guido Rossa 3
I - 20004 Arluno (MI)
Tel : +39 02 903731 / 800 600 633
Deutschland
Linde GmbH
Seitnerstraße 70
D - 82049 Pullach
Tel: +49 89 31001 0 medgas@linde.com
Nederland
Linde Gas Therapeutics Benelux B.V.
De Keten 7
NL - 5651 GJ Eindhoven
Tel: +31 40 282 58 25 info.healthcare.nl@linde.com
Eesti
AS Linde Gas
Valukoja 8
EE - 11415 Tallinn
Tel: +372 650 4500 linde.ee@linde.com
Norge
Linde Gas AS
Postboks 13 Nydalen
N - 0409 Oslo
Tlf. +47 81559095 healthcare.no@linde.com
Ελλάδα
ΛΙΝΤΕ ΕΛΛΑΣ ΜΟΝ ΕΠΕ
Θέση Τρύπιο Λιθάρι
EL – 19600 Μάνδρα Αττικής
Τηλ: +30 211-1045500-510 healthcare.gr@linde.com
Österreich
Linde Gas GmbH
Modecenterstr.17/ Objekt 2/1.OG
A - 1110 Wien
Tel: +43(0)50.4273-2200 healthcare.at@linde.com
España
Linde Gas España, S.A.U.
Camino de Liria, s/n
E - 46530 Puzol (Valencia)
Tel: +34 900 941 857 / +34 902 426 462 lindehealthcare.spain@linde.com
Polska
Linde Gaz Polska Sp. z o.o.
ul. prof. Michała Życzkowskiego 17
PL - 31-864 Krakow
Tel.: +48 (65) 511 89 30 dzialania.niepozadane.pl@linde.com
France
Linde France - Activité médicale - Linde
Healthcare
Z.I. Limay-Porcheville
3 avenue Ozanne
F - 78440 Porcheville
Tél:+33 810 421 000 infotherapies@linde.com
Portugal
Linde Portugal, Lda.
Av. Infante D. Henrique Lotes 21-24
P - 1800-217 Lisboa
Tel: + 351 218 310 420 linde.portugal@linde.com
Hrvatska
Linde Healthcare AB
Rättarvägen 3
S - 169 68 Solna
Tel: +46 8 7311000 healthcare.se@linde.com
România
Linde Gaz România S.R.L.
Str. Avram Imbroane nr. 9
Timisoara 300136 - RO
Tel: +40 256 300 700 healthcare.ro@linde.com
REG-15307/v.43
Page 48/56

Ireland
BOC Ltd.
Forge, 43 Church Street West
Woking, Surrey, GU21 6HT - UK
Tel: 0800 917 4024 ukcsc@inotherapy.co.uk
Slovenija
Linde Healthcare AB
Rättarvägen 3
S - 169 68 Solna
Tel: +46 8 7311000 healthcare.se@linde.com
Ísland
Linde Gas ehf
Breiðhöfða 11
IS - 110 Reykjavik
Sími: + 354 577 3030 healthcare.is@linde.com
Slovenská republika
Linde Gas s.r.o.
Tuhovská 3
SK - 831 06 Bratislava
Tel: +421 800 154 633 sluzby.sk@linde.com
Italia
Linde Medicale S.r.L
Via Guido Rossa 3
I - 20004 Arluno (MI)
Tel : +39 02 903731 / 800 600 633
Suomi/Finland
Oy Linde Gas Ab
Itsehallintokuja 6
FI - 02600 Espoo
Puh/Tel: + 358 10 2421 hctilaus.fi@linde.com
Κύπρος
Linde Hadjikyriakos Gas Ltd
Λεωφόρος Λεμεσού 260, 2029 Στρόβολος
CY - Λευκωσία, Κύπρος.
Τηλ. +357-22482330 info.cy@linde.com
Sverige
Linde Gas AB
Rättarvägen 3
S - 169 68 Solna
Tel: + 46 8 7311800 healthcare.se@linde.com
Latvija
Linde Gas SIA
Skanstes iela 25
LV – 1013 Rīga
Tel: +371 67023900 ksc.lv@linde.com
This leaflet was last revised in MM/YYYY.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
https://www.ema.europa.eu .
REG-15307/v.43
Page 49/56

INOmax contains nitric oxide, a gas used for the treatment of
▪ newborn babies with lung failure associated with high blood pressure in the lungs, a condition known as hypoxic respiratory failure. When inhaled, this gas mixture can improve the flow of blood through the lungs, which may help to increase the amount of oxygen that reaches your baby’s blood.
▪ newborn babies, babies, children, teenagers 0-17 years and adults with high blood pressure in the lungs, connected with heart surgery. This gas mixture can improve heart function and increase the flow of blood through the lungs, which may help to increase the amount of oxygen that reaches the blood.

Do not use INOmax
- If you (as the patient) or your child (as the patient) are allergic (hypersensitive) to nitric oxide or any other ingredients of INOmax (see section 6 ‘further information’ where the full list of ingredients is provided).
- If you have been told that you (as the patient) or your child (as the patient) have an abnormal circulation within the heart.
Warnings and precautions
Inhaled nitric oxide may not always be effective and thus other therapies may be considered necessary for you or your child.
Inhaled nitric oxide may influence the oxygen carrying capacity of the blood. This will be monitored by blood samples and if required the dose of inhaled nitric oxide must be reduced.
REG-15307/v.43
Page 50/56

Nitric oxide may react with oxygen forming nitrogen dioxide that may cause airway irritation. Your or your child’s doctor will undertake monitoring of nitrogen dioxide and in case of elevated values the INOmax therapy will be adjusted, decreased accordingly.
Inhaled nitric oxide may have a mild but influence on the platelets (components that help the blood to clot) of you or your child and any signs of bleeding and or haematoma should be observed. If you see any signs or symptoms that may be associated to bleeding, you should directly inform the doctor.
No effect of inhaled nitric oxide has been documented in newborn babies with a malformation where the diaphragm is not fully complete, so called ‘congenital diaphragmatic hernia’.
In newborn babies with special malformations of the heart, ‘what doctors calls congenital heart defects’ inhaled nitric oxide may cause a worsening of the circulation.
Cases of fluid retention in the lungs have been reported with nitric oxide in patients with disease due to a blocked or narrow vein in the lungs. If you (as a patient) or your child (as a patient) develops shortness of breath or difficulty breathing, contact your doctor immediately.
Children
INOmax should not be used in preterm baby < 34 weeks of gestational age.
Other medicines and INOmax
The doctor will decide when to treat you or your child with INOmax and with other medicines and will carefully supervise the treatment.
Please tell your doctor if you (as the patient) or your child (as the patient) are taking or have recently taken or used any other medicines, including medicines obtained without a prescription.
Some medicines can affect the ability of blood to carry oxygen. These include prilocaine (a local anaesthetic used for pain relief in association to minor painful procedures e.g., suturing, and minor surgical or diagnostic procedures) or glyceryl trinitrate (used to treat chest pain). Your doctor will take care to check that the blood can carry enough oxygen when you are taking these medicines.
Pregnancy and breastfeeding
INOmax is not recommended for use during pregnancy and breastfeeding. Tell your doctor before treatment with INOmax if you are pregnant, think you could be pregnant or are breastfeeding Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Not relevant.
INOmax contains Nitrogen

Your doctor will decide the correct dose of INOmax and will administer INOmax to you or your child’s lungs through a system designed for delivering this gas. This delivery system will ensure that the correct amount of nitric oxide is delivered by diluting INOmax with an oxygen/air mixture immediately before giving it to you.
For you or your child’s safety, the delivery systems intended for administration of INOmax are fitted with devices that constantly measure the amount of nitric oxide, oxygen and nitrogen dioxide (a chemical formed when nitric oxide and oxygen are mixed) being delivered to the lungs.
REG-15307/v.43
Page 51/56

Your doctor will decide how long you or your child should be treated with INOmax.
INOmax is given in dose of 10 to 20 ppm, (maximal dose 20 ppm in children and 40 ppm in adults) part per million of the gas that you or your child inhale. The lowest effective dose will be sought.
Therapy is usually required for about 4 days in newborn infants with lung failure associated with high blood pressure in the lungs. In children and adults with high blood pressure in the lungs, connected with heart surgery, INOmax is usually given for 24-48 hours. However, therapy with INOmax may last longer.
If you or your child receive more INOmax than you should
Too much of inhaled nitric oxide may influence the oxygen carrying capacity of the blood. This will be monitored by blood samples and if required the INOmax dose will be decreased and the administration of medicines such as vitamin C, methylene blue, or eventually blood transfusion, in order to improve the oxygen carrying capacity, may be considered.
If you stop using INOmax
Treatment with INOmax should not be stopped suddenly. Low blood pressure or a rebound increase in pressure in the lungs has been known to occur if treatment with INOmax is stopped suddenly without first lowering the dose.
At the end of treatment, the doctor will slowly lower the amount of INOmax being given to you or your child, so that the circulation in the lungs is able to adjust to oxygen/air without INOmax. Thus, it may take a day or two before you or your child is off INOmax therapy.
If you have any other questions on the use of this medicine, ask your doctor.

Like all medicines, this medicine can cause side effects, although not everybody gets them. The doctor will examine you or your child closely for all side effects.
Side effects that are very commonly seen (affects more than 1 user in 10) in association with INOmax therapy include:
▪
Low platelet count.
Side effects that are commonly seen (affects more than 1 user in 100) in association with INOmax therapy include:
▪ low blood pressure, airless or collapsed lung.
Side effects that may be seen, but uncommonly (affects between 1 user in 100 and 1 user in 1000) are:
▪ increase in methaemoglobin, thus reduced oxygen carrying capacity.
Side effects that may be seen but the frequency is not known (frequency cannot be estimated from the available data) are:
▪
Bradycardia (low cardiac frequency) or too low amount of oxygen in the blood (oxygen desaturation/hypoxemia) due to sudden withdrawal of the treatment ▪ Headache, dizziness, dry throat or shortness of breath following accidental ambient air exposure to nitric oxide (e.g. leakage from equipment or cylinder).
You should directly inform the personnel if you experience headache while being in close proximity to your child receiving INOmax.
REG-15307/v.43
Page 52/56

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, even after you or your child leave the hospital, please tell your doctor.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

Keep this medicine out of the sight and reach of children
Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.
INOmax therapy should only be used and handled by hospital personnel.
▪
INOmax cylinders should be stored secured in order to avoid falling and thus potentially causing harm.
▪
INOmax should be used and administered only by personnel specially trained in the use and handling of INOmax.
All regulations concerning handling of pressurised gas cylinders must be followed.
Storage is supervised by the specialists at the hospital. Gas cylinders are to be stored in well-ventilated rooms or in ventilated sheds where they are protected from rain and direct sunlight.
Protect the gas cylinders from shocks, falls, oxidising and flammable materials, moisture, sources of heat or ignition.
Storage in the pharmacy department
The gas cylinders should be stored in an airy, clean and locked place, for storage of medicinal gas only. Inside this place, a separate premise should be dedicated to the storage of nitric oxide gas cylinders.
Storage in the medical department
The gas cylinder should be put in an equipped site with appropriate material in order to hold the cylinder vertically.
When the gas cylinder is empty, do not discard. Empty gas cylinders will be collected by the supplier.

What INOmax contains
The active substance in INOmax is nitric oxide 800 ppm mol/mol. A 2 litre gas cylinder filled at 155 bar absolute brings 307 litres of gas under pressure of 1 bar at 15oC. A 10 litre gas cylinder filled at 155 bar absolute brings 1535 litres of gas under pressure of 1 bar at 15oC.
The other ingredient is nitrogen.
What INOmax looks like and contents of the pack
Medicinal gas, compressed
REG-15307/v.43
Page 53/56

A 2 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection and a standard valve hand-wheel.
A 2 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection and a INOmeter device equipped valve hand-wheel.
A 10 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection and a standard valve hand-wheel.
A 10 litre aluminium gas cylinder (identification with aquamarine shoulder and white body) filled under a pressure of 155 bar, equipped with a stainless steel positive pressure (residual) valve with a specific outlet connection and a INOmeter device equipped valve hand-wheel.
INOmax is available in 2 litre and 10 litre aluminium gas cylinder.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Linde Healthcare AB
Rättarvägen 3
169 68 Solna
Sweden
Manufacturer
Linde France
Z.I. Limay Porcheville
3 avenue Ozanne
78440 Porcheville
France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Linde Gas Belgium N.V.
Borsbeeksebrug 34
B - 2600 Antwerpen
Tél/Tel.: +32 70 233 826 info.healthcare.be@linde.com
Lietuva
Linde Gas UAB
Didlaukio g. 69
LT - 08300 Vilnius
Tel.: +370 2787787 administracija.lt@linde.com
България
Linde Healthcare AB
Rättarvägen 3
S - 169 68 Solna
Швеция
Tel: +46 8 7311000 healthcare.se@linde.com
Luxembourg/Luxemburg
Linde Gas Belgium N.V.
Borsbeeksebrug 34
B - 2600 Antwerpen
Belgique/Belgien
Tél/Tel.: +32 70 233 826 info.healthcare.be@linde.com
REG-15307/v.43
Page 54/56

Česká republika
Linde Gas a.s.
U Technoplynu 1324
CZ - 198 00 Praha 9
Tel: +420 800 121 121 info.cz@linde.com
Magyarország
Linde Gáz Magyarország Zrt.
Illatos út 11/A.
H - 1097 Budapest
Tel.: +36 30 349 2237 tunde.bencze@linde.com
Danmark
Linde Gas A/S
Lautruphøj 2-6
DK - 2750 Ballerup
Tlf.: + 45 70 104 103 healthcare.dk@linde.com
Malta
Linde Medicale S.r.L
Via Guido Rossa 3
I - 20004 Arluno (MI)
Tel : +39 02 903731 / 800 600 633
Deutschland
Linde GmbH
Seitnerstraße 70
D - 82049 Pullach
Tel: +49 89 31001 0 medgas@linde.com
Nederland
Linde Gas Therapeutics Benelux B.V.
De Keten 7
NL - 5651 GJ Eindhoven
Tel: +31 40 282 58 25 info.healthcare.nl@linde.com
Eesti
AS Linde Gas
Valukoja 8
EE - 11415 Tallinn
Tel: +372 650 4500 linde.ee@linde.com
Norge
Linde Gas AS
Postboks 13 Nydalen
N - 0409 Oslo
Tlf. +47 81559095 healthcare.no@linde.com
Ελλάδα
ΛΙΝΤΕ ΕΛΛΑΣ ΜΟΝ ΕΠΕ
Θέση Τρύπιο Λιθάρι
EL – 19600 Μάνδρα Αττικής
Τηλ: +30 211-1045500-510 healthcare.gr@linde.com
Österreich
Linde Gas GmbH
Modecenterstr.17/ Objekt 2/1.OG
A - 1110 Wien
Tel: +43(0)50.4273-2200 healthcare.at@linde.com
España
Linde Gas España, S.A.U.
Camino de Liria, s/n
E - 46530 Puzol (Valencia)
Tel: +34 900 941 857 / +34 902 426 462 lindehealthcare.spain@linde.com
Polska
Linde Gaz Polska Sp. z o.o.
ul. prof. Michała Życzkowskiego 17
PL - 31-864 Krakow
Tel.: +48 (65) 511 89 30 dzialania.niepozadane.pl@linde.com
France
Linde France - Activité médicale - Linde
Healthcare
Z.I. Limay-Porcheville
3 avenue Ozanne
F - 78440 Porcheville
Tél:+33 810 421 000 infotherapies@linde.com
Portugal
Linde Portugal, Lda.
Av. Infante D. Henrique Lotes 21-24
P - 1800-217 Lisboa
Tel: + 351 218 310 420 linde.portugal@linde.com
Hrvatska
Linde Healthcare AB
Rättarvägen 3
S - 169 68 Solna
Tel: +46 8 7311000 healthcare.se@linde.com
România
Linde Gaz România SRL
Str. Avram Imbroane nr. 9
Timisoara 300136 - RO
Tel: +40 256 300 700 healthcare.ro@linde.com
REG-15307/v.43
Page 55/56

Ireland
BOC Ltd.
Forge, 43 Church Street West
Woking, Surrey, GU21 6HT - UK
Tel: 0800 917 4024 ukcsc@inotherapy.co.uk
Slovenija
Linde Healthcare AB
Rättarvägen 3
S - 169 68 Solna
Tel: +46 8 7311000 healthcare.se@linde.com
Ísland
Linde Gas ehf
Breiðhöfða 11
IS - 110 Reykjavik
Sími: + 354 577 3030 healthcare.is@linde.com
Slovenská republika
Linde Gas s.r.o.
Tuhovská 3
SK - 831 06 Bratislava
Tel: +421 2 49 10 25 16 healthcare.sk@linde.com
Italia
Linde Medicale S.r.L
Via Guido Rossa 3
I - 20004 Arluno (MI)
Tel : +39 02 903731 / 800 600 633
Suomi/Finland
Oy Linde Gas Ab
Itsehallintokuja 6
FI - 02600 Espoo
Puh/Tel: + 358 10 2421 hctilaus.fi@linde.com
Κύπρος
Linde Hadjikyriakos Gas Ltd
Λεωφόρος Λεμεσού 260, 2029 Στρόβολος
CY - Λευκωσία, Κύπρος.
Τηλ. +357-22482330 info.cy@linde.com
Sverige
Linde Gas AB
Rättarvägen 3
S - 169 68 Solna
Tel: + 46 8 7311800 healthcare.se@linde.com
Latvija
Linde Gas SIA
Skanstes iela 25
LV – 1013 Rīga
Tel: +371 67023900 ksc.lv@linde.com
This leaflet was last revised in MM/YYYY.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
https://www.ema.europa.eu.
REG-15307/v.43
Page 56/56